Alkermes PLC

ALKS

Equity

ISIN IE00B56GVS15 / Valor 13920929

NASDAQ (2026-06-23)

USD 48.07+4.45%

Alkermes PLC
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Alkermes PLC is a biopharmaceutical company focused on the development and commercialization of medicines for the treatment of psychiatric and neurological disorders, areas known for their complexity and the significant challenges they pose in treatment. Leveraging its deep expertise in neuroscience, Alkermes aims to address the unmet needs of patients suffering from conditions that are often difficult to treat and historically subject to stigma. The company's portfolio includes both marketed medicines and investigational drugs that are currently in various stages of clinical development. Alkermes emphasizes a patient-centric approach in its research and development efforts, striving to innovate in fields where therapeutic options are limited or inadequate. Through its integrated research strategy and specialized commercial infrastructure, Alkermes is committed to delivering new treatment options that can potentially transform the management of psychiatric and neurological diseases, underscoring its dedication to making a meaningful difference in patients' lives.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

64.3%1Y

44.2%3Y

98.9%5Y

Performance

40.3%1Y

37.6%3Y

37.6%5Y

Volatility